Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ocugen Inc
(NQ:
OCGN
)
1.270
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ocugen Inc
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
OCUGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ocugen, Inc. and Encourages Investors to Contact the Firm
April 11, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
April 11, 2024
From
Schall Law
Via
GlobeNewswire
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Ocugen, Inc. (OCGN)
April 11, 2024
From
Robbins LLP
Via
GlobeNewswire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc. Incorporated Investors – OCGN
April 11, 2024
From
Rosen Law Firm
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
April 10, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
April 10, 2024
From
Ocugen
Via
GlobeNewswire
OCUGEN LOSS ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Inquire About Securities Class Action Investigation – OCGN
April 09, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
April 08, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
April 05, 2024
From
Ocugen
Via
GlobeNewswire
OCUGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Ocugen, Inc. on Behalf of Ocugen Stockholders and Encourages Investors to Contact the Firm
April 02, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
April 02, 2024
Conference Call and Webcast Today at 8:30 a.m. ET
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
April 01, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
April 01, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
March 18, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
March 13, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at Investing in Cures Summit
March 06, 2024
From
Ocugen
Via
GlobeNewswire
Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB
February 28, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Ocugen Clinical Showcase Webcast Now Available
February 28, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
February 22, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at 2024 BIO CEO & Investor Conference
February 21, 2024
From
Ocugen
Via
GlobeNewswire
Healthcare Innovations and Collaborations Fuel Industry Expansion Stocks Under $1 Look Now! OCGN, VTAK, RSCI, VERU, AGEN
February 20, 2024
Via
AB Newswire
Exposures
Product Safety
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
February 14, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at Pharma Market Research Conference
January 31, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
January 16, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design
December 21, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
December 19, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
December 13, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
November 29, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
November 10, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
November 09, 2023
From
Ocugen
Via
GlobeNewswire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.